Selective Impairment of CD4 + CD25 + Foxp3 + Regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis

International Immunopharmacology

Volumn 11, Issue 2, 2011, Pages 212-219

  Liu, Nan ^a   Zheng, Yijie ^a   Zhu, Ying ^a   Xiong, Shudao ^a   Chu, Yiwei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; CD4 + CD25 + Foxp3 + T cells; Chemo immunotherapy; Lung cancer; Paclitaxel

Indexed keywords

PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EFFECTOR CELL; FEMALE; IN VITRO STUDY; LEWIS CARCINOMA; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 79151475547     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.11.021     Document Type: Article

References (31)

1. F.A. Fitzpatrick, and R. Wheeler The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents Int Immunopharmacol 3 2003 1699 1714
2. M. Kobayashi, J. Sakamoto, T. Namikawa, K. Okamoto, T. Okabayashi, and K. Ichikawa Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients World J Gastroenterol 12 2006 1412 1415
3. A.J. Barrett, and B.N. Savani Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 23 2009 53 58
4. C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, and C. Williams Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann Oncol 18 2007 409 420
5. D.W. Mullins, C.J. Burger, and K.D. Elgert Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide J Immunol 162 1999 6811 6818
6. L.W. Pfannenstiel, S.S. Lam, L.A. Emens, E.M. Jaffee, and T.D. Armstrong Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice Cell Immunol 263 2010 79 87
7. H.G. Joo Altered maturation of dendritic cells by taxol, an anticancer drug J Vet Sci 4 2003 229 234
8. M. Kubo, T. Morisaki, K. Matsumoto, A. Tasaki, N. Yamanaka, and H. Nakashima Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production Cancer Immunol Immunother 54 2005 468 476
9. L. Zhang, K. Dermawan, M. Jin, R. Liu, H. Zheng, and L. Xu Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy Clin Immunol 129 2008 219 229
10. T. Takahashi, and S. Sakaguchi Naturally arising CD25 + CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease Curr Mol Med 3 2003 693 706
11. S. Danese, and S. Rutella The Janus face of CD4 + CD25+ regulatory T cells in cancer and autoimmunity Curr Med Chem 14 2007 649 666
12. Kandulski A., Malfertheiner P., and Wex T. Role of regulatory T-cells in H. pylori-induced gastritis and gastric cancer Anticancer Res 30 2010 1093 1103
13. F.X. Qin Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host Cell Mol Immunol 6 2009 3 13
14. A.M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 9 2003 606 612
15. Y. Chu, L.X. Wang, G. Yang, H.J. Ross, W.J. Urba, and R. Prell Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma J Immunother 29 2006 367 380
16. C. Ferlini, L. Cicchillitti, G. Raspaglio, S. Bartollino, S. Cimitan, and C. Bertucci Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77 Cancer Res 69 2009 6906 6914
17. A.P. Vicari, R. Luu, N. Zhang, S. Patel, S.R. Makinen, and D.C. Hanson Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse Cancer Immunol Immunother 58 2009 615 628
18. Z. Liu, J.H. Kim, L.D. Falo Jr., and Z. You Tumor regulatory T cells potently abrogate antitumor immunity J Immunol 182 2009 6160 6167
19. X. Cao Regulatory T cells and immune tolerance to tumors Immunol Res 46 2010 79 93
20. Langroudi L., Hassan Z.M., Ebtekar M., Mahdavi M., Pakravan N., and Noori S. A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model Int Immunopharmacol 5 2010 10.1016/j.intimp.2010.06.005
21. A.M. Ibrado, Y. Huang, G. Fang, and K. Bhalla Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis Cell Growth Differ 7 1996 1087 1094
22. M.A. Jordan, K. Wendell, S. Gardiner, W.B. Derry, H. Copp, and L. Wilson Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death Cancer Res 56 1996 816 825
23. C.G. Milross, K.A. Mason, N.R. Hunter, W.K. Chung, L.J. Peters, and L. Milas Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel J Natl Cancer Inst 88 1996 1308 1314
24. Srivastava R.K., Mi Q.S., Hardwick J.M., and Longo D.L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis Proc Natl Acad Sci USA 7 1999 3775 3780
25. C. Ferlini, G. Raspaglio, S. Mozzetti, M. Distefano, F. Filippetti, and E. Martinelli Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance Mol Pharmacol 64 2003 51 58
26. Z. Huang Bcl-2 family proteins as targets for anticancer drug design Oncogene 19 2000 6627 6631
27. B. Antonsson Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion Cell Tissue Res 306 2001 347 361
28. M.J. Pinkoski, and D.R. Green Lymphocyte apoptosis: refining the paths to perdition Curr Opin Hematol 9 2002 43 49
29. L. Qiao, Z. Xu, T. Zhao, Z. Zhao, M. Shi, and R.C. Zhao Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model Cell Res 18 2008 500 507
30. Y. Tabuchi, J. Matsuoka, M. Gunduz, T. Imada, R. Ono, and M. Ito Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer Int J Oncol 34 2009 313 319
31. M. Zhou, Z. Liu, Y. Zhao, Y. Ding, H. Liu, and Y. Xi MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression J Biol Chem 285 2010 21496 21507